The Food and Drug Administration approved the first oral PCSK9 inhibitor on July 16, giving patients who need further LDL cholesterol reduction a daily pill option in a drug class that has been available only by injection.
Enlicitide, sold as Lipfendra, is a 20 milligram once-daily tablet approved as an adjunct to diet and exercise for adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia.
